Everything below concerns triagonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-15. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Oxidative deamination is a form of deamination that generates α-keto acids and other oxidized products from amine-containing compounds, and occurs primarily in the liver. Oxidative deamination is stereospecific, meaning it contains different stereoisomers as reactants and products; this process is either catalyzed by L or D- amino acid oxidase and L-amino acid oxidase is present only in the liver and kidney. Oxidative deamination is an important step in the catabolism of amino acids, generating a more metabolizable form of the amino acid, and also generating ammonia as a toxic byproduct. The ammonia generated in this process can then be neutralized into urea via the urea cycle. Much of the oxidative deamination occurring in cells involves the amino acid glutamate, which can be oxidatively deaminated by the enzyme glutamate dehydrogenase (GDH), using NAD or NADP as a coenzyme. This reaction generates α-ketoglutarate (α-KG) and ammonia. Glutamate can then be regenerated from α-KG via the action of transaminases or aminotransferase, which catalyze the transfer of an amino group from an amino acid to an α-keto acid. In this manner, an amino acid can transfer its amine group to glutamate, after which GDH can then liberate ammonia via oxidative deamination. This is a common pathway during amino acid catabolism. Another enzyme responsible for oxidative deamination is monoamine oxidase, which catalyzes the deamination of monoamines via addition of oxygen. This generates the corresponding ketone- or aldehyde-containing form of the molecule, and generates ammonia.
==== Mesocorticolimbic pathway ==== Understanding the pathways in which drugs act and how drugs can alter those pathways is key when examining the biological basis of drug addiction. The reward pathway, known as the mesolimbic pathway, or its extension, the mesocorticolimbic pathway, is characterized by the interaction of several areas of the brain. Dopaminergic neurons in the ventral tegmental area (VTA) fire in response to cues that predict a reward and project to the nucleus accumbens through the mesolimbic pathway; nearly all addictive drugs increase dopamine release along this pathway, although they act on it by different routes. The nucleus accumbens, made up largely of GABAergic medium spiny neurons, is a principal target of these projections and is involved in learning conditioned responses to drug-associated cues, and in the growing sensitivity to those cues as addiction progresses. A further target is the prefrontal cortex, including the anterior cingulate and orbitofrontal cortices, which weighs competing information in determining whether a behavior is carried out and forms the associations between drug reward and environmental cues that give those cues their power. These cues are strong mediators of drug-seeking behavior and can trigger relapse even after months or years of abstinence.
== External links == McLetchie, N. G. (2002). "Alloxan Diabetes, a Discovery, albeit a Minor one" (PDF). Journal of the Royal College of Physicians of Edinburgh. 32 (2): 134–142. doi:10.1177/1478271520023202014. PMID 12434795. The history and chemistry of the Murexide dye Archived 2013-05-05 at the Wayback Machine
== Regulatory history == The device was evaluated under an investigational device exemption in the United States, where it was compared against transforaminal lumbar interbody fusion. It was later granted FDA Breakthrough Device designation in 2021, followed by full FDA approval in 2023 after demonstrating superiority over fusion in composite clinical success. The TOPS System also holds CE marking, signifying that it meets health, safety, and environmental requirements for sale in the European Economic Area.
Sources: en.wikipedia.org
Introduced in the 1950s, the population of Nile perch in Lake Victoria has been targeted for its maw since the mid-2010s in Uganda, Kenya and Tanzania. Originally, skiff owners contract fishermen to fish for perch; the owners pay the fishermen, retain the fish and sell the maws to fish maw export companies. In 2018, the Government of Uganda introduced a law where the fish maw could not be removed until resale to a fish processing plant; official production of fish maw dropped sharply, possibly due to under-reporting from smuggling. In 2021, the government introduced a 7-percent export tariff on fish maw, in anticipation of a Chinese trade deal; the September 2024 Forum on China–Africa Cooperation eliminated the tariffs.
Since the PTD, the hydroxyapatite tablets are not preferentially orientated; they are under less compressive residual stress, causing the microtubules to act as crack initiation sites. This manifests as cross-hatched shear microcracks forming at the microtubules in compression and as ring-shaped microcracks in tension. The tip of a larger crack creates a stress concentration that helps initiate microcracks around the microtubules ahead of it, consuming energy and resisting further damage. The imperfect linking of the microcrack to a larger crack also induces 'uncracked ligaments', which help arrest the larger crack. In comparison, enamel does not display the same fracture resistance, and fractures traveling across the DEJ are usually stopped within ~10 μm. The combination of the residual stress and the perpendicular orientation of the ITD mineralized collagen fibers significantly increases the fracture toughness and fatigue endurance limit along the microtubule direction.
Biopolymers are natural polymers produced by the cells of living organisms. Like other polymers, biopolymers consist of monomeric units that are covalently bonded in chains to form larger molecules. There are three main classes of biopolymers, classified according to the monomers used and the structure of the biopolymer formed: polynucleotides, polypeptides, and polysaccharides. The polynucleotides, RNA and DNA, are long polymers of nucleotides. Polypeptides include proteins and shorter polymers of amino acids; some major examples include collagen, actin, and fibrin. Polysaccharides are linear or branched chains of sugar carbohydrates; examples include starch, cellulose, and alginate. Other examples of biopolymers include natural rubbers (polymers of isoprene), suberin and lignin (complex polyphenolic polymers), cutin and cutan (complex polymers of long-chain fatty acids), melanin, and polyhydroxyalkanoates (PHAs).
=== Altered glycan theory === According to this theory, the effector function of the immune response is mediated by the glycans (polysaccharides) displayed by the cells and humoral components of the immune system. Individuals with autoimmunity have alterations in their glycosylation profile such that a proinflammatory immune response is favored. It is further hypothesized that individual autoimmune diseases will have unique glycan signatures.
=== Osteocyte === Osteocytes are cells of mesenchymal origin and originate from osteoblasts that have migrated into and become trapped and surrounded by a bone matrix that they themselves produced. The spaces the cell body of osteocytes occupy within the mineralized collagen type I matrix are known as lacunae, while the osteocyte cell processes occupy channels called canaliculi. The many processes of osteocytes reach out to meet osteoblasts, osteoclasts, bone lining cells, and other osteocytes probably for the purposes of communication. Osteocytes remain in contact with other osteocytes in the bone through gap junctions—coupled cell processes which pass through the canalicular channels.
Sources: en.wikipedia.org
=== Pancreatic cancer cells === This type of collagen can cause an increase in pancreatic cancer cells and is able to inhibit apoptosis through an autocrine loop. This autocrine loop provides essential cell survival signals to the pancreatic cancer cells. Type IV collagen is expressed close to the cancer cells in vivo, forming basement membrane like structures on the cancer cell surface that colocalize with the integrin receptors. The interaction between type IV collagen produced by the cancer cell, and integrins on the surface of the cancer cells, are important for continuous cancer cell growth, maintenance of a migratory phenotype, and for avoiding apoptosis.
Thrombotic thrombocytopenic purpura - uncommon and potentially fatal thrombotic microangiopathy characterized by severe thrombocytopenia, organ ischemia connected to diffuse microvascular platelet rich-thrombi, and microangiopathic hemolytic anemia. Relapsing polychondritis - uncommon multisystem autoimmune disease with an unclear etiology that is marked by progressive cartilaginous tissue loss and recurring episodes of inflammation. Mixed connective tissue disease - systemic autoimmune disease that shares characteristics with two or more other systemic autoimmune diseases, such as rheumatoid arthritis, polymyositis/dermatomyositis, systemic lupus erythematosus, and systemic sclerosis. It is an example of overlap syndrome. Undifferentiated connective tissue disease - unclassifiable systemic autoimmune disorders that do not meet any of the current classification requirements for connective tissue diseases, yet have clinical and serological signs similar to connective tissue diseases. Psoriatic arthritis - inflammatory musculoskeletal condition linked to psoriasis. Cryoglobulinemia - condition sometimes associated with systemic lupus erythematosus or rheumatoid arthritis in which there are abnormal proteins in the blood. IgG4-related disease - chronic inflammatory condition in which there is deposition of connective tissue (fibrosis) in different organs. Potentially life-threatening. Periaortitis - a group of rare vascular inflammatory diseases in which fibrous inflammatory tissue develops around the aorta or other structures such as the ureters.
== Treatment for collagen loss == Some of the causatives that break down collagen include spending too much time in the sun, smoking, dehydration, and stress. Thus, loss of collagen can be prevented via dietary changes, which may increase the turnover of cells and increase the creation of collagen, as well as lifestyle changes, including applying an adequate amount of sunscreen to prevent UV rays from the sun from damaging the skin and partaking in stress-relieving activities. Other interventions, such as taking vitamins C and A, can provide a boost to collagen production in the body. Consuming nutritious foods rich in the necessary vitamins, minerals, and amino acids promotes collagen production and reduces cellular damage within the body.
== Research == Lemborexant is under development for the treatment of circadian rhythm sleep disorders, sleep apnea, and chronic obstructive pulmonary disease. As of February 2022, it is in phase 2 clinical trials for circadian rhythm sleep disorders and phase 1 trials for sleep apnea and chronic obstructive pulmonary disease.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.